Sickle Cell Patients Weigh Clinical Trial Participation At FDA Meeting
Executive Summary
At the fifth disease area meeting under PDUFA V’s patient-focused drug development initiative, patients with sickle cell disease talk about how they want their physicians to be more aware of potential studies.
You may also be interested in...
FDA Looking To Boost Transparency On How Patient Input Is Used In Drug Reviews
Sponsor concerns about commercial confidential information may be a sticking point in getting patient groups the desired data on when and how the FDA uses patient input in regulatory decision making.
Case Studies: How Patient Input Is Changing R&D
US FDA's patient-focused drug development meeting on sickle cell disease inspired Global Blood Therapeutics to develop a new patient-reported outcomes instrument, while an externally led meeting on amyloidosis confirmed for Alnylam that its pivotal trial was studying clinically meaningful secondary endpoints.
“Patient Voice” Report Puts Chronic Fatigue Symptoms, Treatments In Benefit/Risk Framework
FDA report on CFS/myalgic encephalomyelitis is first of its kind from the patient-focused drug development initiative under PDUFA V. Incorporating comments from hundreds of patients and caregivers into a structured framework shows how the input may support a benefit/risk assessment for new products.